The PR almost screams "Kevetrin WORKS." There's no way they'd be even considering a trial as a monotherapy if they hadn't had mind-blowing results with these Stage 4 TERMINAL cancer patients. Remember that the CEO said that the thymus cancer patient (TERMINAL) had survived 11 months, and he hoped he would have "many years" of health.

Now, after literally years of telling us that they were looking at Kevetrin to be used as an adjunct to other therapies, they are telling us they're going to test it by itself.

Kevetrin has to have had some incredibly compelling results for that to be happening.

My opinion: Kevetrin WORKS.